Canine hemangiosarcoma (HSA) is a highly malignant tumour associated with short survival times because of early and widespread metastasis. In humans and rodents, monocytes play key roles in promoting tumour metastasis through stimulating tumour cell extravasation, seeding, growth and angiogenesis. Therefore, we investigated the potential association between monocyte infiltration and tumour metastasis in HSA and other common canine tumours. Immunohistochemistry was used to quantify CD18 + monocytes within metastases. We found that HSA metastases had significantly greater numbers of CD18 + monocytes compared with metastases from other tumour types. HSA cells were the highest producers of the monocyte chemokine CCL2, and stimulated canine monocyte migration in a CCL2 dependent manner. These results are consistent with the hypothesis that overexpression of CCL2 and recruitment of large numbers of monocytes may explain in part the aggressive metastatic nature of canine HSA. Thus, therapies designed to block monocyte recruitment may be an effective adjuvant strategy for suppressing HSA metastasis in dogs.
Introduction
Hemangiosarcoma (HSA) is a malignant vascular neoplasm to which dogs appeared predisposed relative to other species. 1, 2 For example, HSA comprises 5-7% of all non-cutaneous malignant canine neoplasms, with the most common sites including the right atrium/auricle, spleen and the skin. 3 -10 Based on its histomorphological appearance, the tumour is presumed to arise from transformed endothelial cells; however, the tumours' origins are still under debate, and more recent investigations suggest that HSA likely originates from haematopoietic endothelial progenitor cells. 11 -13 In the dog, HSA is characterized by very aggressive biological behaviour and a high rate of rapid and widespread metastasis, with 1-year survival rates following surgery and/or adjuvant chemotherapy reported to be less than 10%. 14 -17 Current standard of care for canine HSA includes surgical removal of the primary tumour, followed by adjuvant chemotherapy. 14 -16,18,19 However, the benefits of adjuvant chemotherapy are modest at best with median survival times reported to be 6 months or less in multiple, independent studies. 14,15,18 -20 Alternative treatment modalities for canine HSA have been evaluated, including addition of the anti-angiogenic drug minocycline or the non-specific immune stimulant L-MTP-PE to DOX therapy, doxorubicin dose intensification, and combination metronomic therapy with etoposide, cyclophosphamide and piroxicam, but with little evidence of improved survival times. 14, 16, 20 -22 Our critical knowledge gaps in understanding the highly malignant nature of HSA currently limit our ability to devise new therapeutic approaches.
Inflammatory monocytes have been shown to play key roles in promoting tumour metastasis in both humans and preclinical rodent models. 23, 24 In contrast to conventional or steady state monocytes, the numbers of inflammatory monocytes, which are defined in part by their high surface expression of the chemokine receptor CCR2, vary widely in the bloodstream in response to inflammatory stimuli. 24 Both tumour cells and stromal cells at sites of metastases have been shown to produce abundant amounts of the monocyte chemokine CCL2, the primary ligand for the CCR2 molecule. 24 Thus, the CCL2-CCR2 chemotactic axis serves to stimulate recruitment of inflammatory monocytes to metastatic sites, where the monocytes can then differentiate into metastasis-associated macrophages (MAMs). 23 -26 These MAMs in turn function to prepare the metastatic microenvironment for the arrival of tumour cells by producing key cytokines and growth factors, including vascular endothelial growth factor (VEGF). 23 -26 These macrophage-derived soluble factors are critical to the multistep processes of tumour cell extravasation, survival, growth and angiogenesis, which are required for the efficient colonization and subsequent outgrowth of tumour cells at the metastatic site. Multiple studies have demonstrated that high serum CCL2 concentrations and elevated circulating monocyte counts are both negative prognostic factors for a variety of cancers in humans, including melanoma, lymphoma and carcinomas of the prostate, colon, and kidney, among others. 27 -33 Moreover, we have also demonstrated that increased numbers of circulating monocytes are also negative prognostic factors for canine lymphoma and osteosarcoma. 34, 35 Elevated serum concentrations of CCL2 were also associated with shorter disease-free intervals in canine B cell lymphoma. 34 Previous studies have evaluated macrophage infiltrates in canine melanoma, mammary carcinoma, seminoma, glioma and nasal carcinoma. 36 -40 In canine mammary tumours, an association between a high density of tumour-associated macrophages (TAMs) and significantly decreased overall survival times was reported. 39 However, to our knowledge, monocytes have not been quantitated in canine tumours, especially in tumour metastases. Nor have mechanisms regulating monocyte recruitment by tumours been investigated. Therefore, the purpose of this study was to characterize the density of tumour-associated monocytes within pulmonary metastases of several common canine tumours, and to investigate tumour-produced factors that mediate monocyte migration.
In the studies reported here, we found that HSA in dogs was uniquely associated with a high density of infiltrating CD18 + monocytes. Potential mechanisms of monocyte recruitment were also evaluated by means of in vitro and in vivo assays. The findings from these studies demonstrated an important role for the CCL2-CCR2 axis in regulating monocyte recruitment and promoting HSA metastasis in dogs, and suggest that monocyte recruitment may explain in part the highly aggressive metastatic nature of canine HSA. The findings also provide a rationale for immunotherapeutic interventions to interrupt monocyte and macrophage recruitment to sites of HSA metastasis in dogs.
Materials and methods

Tumour tissues
Formalin-fixed, paraffin-embedded (FFPE) tissues of pulmonary metastases of various canine tumour types were obtained from archived cases submitted to the Colorado State University Veterinary Diagnostic Laboratory (CSU-VDL) for post-mortem evaluation between the years of 2007 and 2014. Evaluated tumour types included HSA (n = 18), osteosarcoma (n = 11), transitional cell carcinoma (n = 4), melanoma (n = 5) and soft tissue sarcoma (n = 4). Necropsy reports from the CSU-VDL database were reviewed, and sections were cut and haematoxylin-eosin stained to confirm the previous diagnoses.
Immunohistochemistry
Tissue blocks were sectioned at 5 μm, mounted on Superfrost Plus slides (Fisher Scientific, Pittsburgh, PA, USA) and immunolabelling for the -2 integrin, pan-leukocyte marker CD18, and chemokine CCL2, was performed using standard methods. Briefly, tissue slides were de-paraffinized in xylenes and rehydrated using a series of graded alcohols. Antigen retrieval was performed using either: (1) A proprietary Leica Bond enzyme-1 (Buffalo Grove, IL, USA) enzymatic retrieval for 10 min (CD18); or (2) 10 mM sodium citrate buffer, pH 6.0, for 20 min at 125 ∘ C in a pressurized chamber (CCL2). Immunolabelling was performed using either a Leica Bond Max autostainer (CD18), or Dako autostainer link 48 (CCL2) (Dako, Carpinteria, CA, USA). Tissues were blocked for endogenous peroxidase by incubation in 3% H 2 0 2 for 5 min. Subsequently, sections were then incubated with the following primary antibodies for 1 h at room temperature (RT): mouse canine CD18 (clone CA16.3C10), or rabbit human CCL2 (Abcam, ab9669, 2.5 μg/ml) (Abcam, Cambridge, MA USA). For CCL2, detection was performed using the universal-labelled streptavidin-biotin2 system (Dako), which consists of incubation with a mixture of biotinylated goat antimouse and rabbit IgG secondary antibodies followed by horseradish peroxidase-labelled streptavidin. For CD18, detection was performed using the Leica Bond Polymer Red Refine Detection (Buffalo Grove, IL, USA) system, which consists of an alkaline phosphatase-linked rabbit antimouse IgG. Positive staining was visualized using either refine red (CD18) or DAB (CCL2) chromogen substrates.
CCL2 immunofluorescence
For intracellular CCL2 immunofluorescent staining, canine tumour cells (100 000 cells) in complete MEM media were grown on sterilized glass coverslips (Fisher Scientific, Waltham, MA, USA) in 24-well plates for 24 h ± a protein transport inhibitor (Brefeldin A, 10 μg\mL, BioLegend, San Diego, CA, USA) for the last 4 h of culture. After 24 h, cells were fixed in 1% paraformaldehyde for 10 min on ice, and then permeabilized via incubation with 0.1% Triton-X100 in PBS containing 0.5% Tween20 (PBST) for 15 min at RT. Non-specific binding was blocked by 30 min incubation with 5% donkey serum in 1% bovine serum albumin (BSA) (Calbiochem, San Diego, CA, USA). Coverslips were incubated with the primary antibody [rabbit human CCL2 (Abcam, ab9669, 2.5 μg/mL) diluted in 1% BSA containing 0.1% Triton-X100 for 1 h at RT]. Positive CCL2 labelling was visualized using a FITC-labelled donkey rabbit IgG secondary antibody (Jackson ImmunoResearch, West Grove, PA, USA). Nuclei were counterstained with DAPI, and coverslips mounted onto glass slides using Fluoromount aqueous mounting media (SigmaAldrich, St. Louis, MO, USA).
Western blot for cross-species validation of the antihuman CCL2 antibody
A total of 1 μg of recombinant canine CCL2 (R&D systems, Minneapolis, MN, USA) was mixed 1:1 with ×2 Laemelli sample buffer containing 5% 2-Mercaptoethanol (BioRad Laboratories, Hercules, CA, USA), boiled for 5 min, cooled on ice, and then loaded in a 20 L volume into a Mini-Protean TGX 4-20% precast polyacrylamide gel (BioRad Laboratories) for sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). SDS-PAGE was performed at 150 V for approximately 1 h. Protein was then wet transferred to nitrocellulose membranes (95 V, 50 min, at 4 ∘ C), and membranes were blocked for 1 h at RT in a 5% non-fat dry milk in Tris-buffered saline Tween 20 solution (TBST). After washing in TBST, membranes were incubated with the primary antibody (1.25 μg/mL rabbit antihuman CCL2, abcam9669) diluted in 5% non-fat dry milk in TBST, overnight at 4 ∘ C. The following day, membranes were rinsed (×3 with TBST), incubated with the secondary antibody (HRP-linked goat antirabbit IgG; Thermo Scientific, Waltham, MA, USA) diluted 1:20 000 in 5% milk-TBST for 1 h at RT. Lastly, membranes were imaged with chemiluminescent substrate (Clarity Western ECL, BioRad) using a Chemi Doc XES + system (BioRad).
Image analysis and quantification
For the quantification of CD18+ immunoreactivity, (5-8) 40x magnification, intratumoural independent fields of multiple pulmonary metastases of each tumour were captured using standardized exposure times and either a Nikon (Melville, NY, USA) 80i microscope and Olympus (Center Valley, PA, USA) DP70 camera, or an Olympus IX83 microscope and Olympus SC30 camera. In order to ensure accurate quantitative assessment of CD18+ cells, we used the colour deconvolution algorithm developed for the NIH open-source image analysis software, ImageJ. Using the FastRed and FastBlue vectors for this algorithm, digitized intratumoural images of tumour metastases were separated in into 8-bit grey scale images representative of the chromogen colour (red) only. A lower threshold limit was then set at a value corresponding to the mean of the isotype control, and universally applied to every single image. Any pixel value falling above this lower threshold value was measured as positive for CD18, and used to determine % area positive within the field. For quality control, image masks of the 'thresholded', positive counted area were also generated and directly visually compared with the originally captured photomicrographs by a board-certified pathologist, to ensure accuracy in representation of CD18+ immunoreactivity ( 
Tumour cell culture
The DEN-HSA cell line was used for all in vitro monocyte migration and CCL2 immunofluorescence and ELISA assays. The DEN-HSA cell line was provided by Dr Doug Thamm (Flint Animal Cancer Center), and was originally derived at the University of Wisconsin, Madison, WI from a spontaneous renal HSA of a Golden Retriever. 41 Cells were maintained in MEM culture media (Gibco, Grand Island, NY, USA) supplemented with 10% foetal bovine serum (Atlas Biologicals, Fort Collins, CO, USA), penicillin (100 U/mL), streptomycin (100 μg/mL), L-glutamine (2 mM), and non-essential amino acids (0.1 mM) (All obtained from Gibco). Cells were grown on standard plastic tissue culture flasks (Cell Treat, Shirley, MA, USA), incubated under standard conditions of 37 ∘ C, 5% CO 2 , and humidified air.
In vitro monocyte migration assays and CCL2 neutralization
Peripheral Blood Mononuclear Cells (PBMCs) were isolated from fresh, EDTA-treated canine blood and used for in vitro trans-well migration assays to assess the degree to which HSA tumourconditioned media elicited canine monocyte migration. For generation of tumour-conditioned media, 100 000 DEN-HSA tumour cells were plated in a 24-well plate (Falcon, Tewksbury, MA USA) in 1 mL of complete MEM media and grown for approximately 24 h prior to harvest of the culture supernatant. A total of 600 L of HSA-conditioned media was placed in the 24-well plate below each migration chamber to serve as the chemoattractant for the PBMCs. The negative control consisted of 600 L of complete MEM media alone. The positive control consisted of 600 L of complete MEM media containing 100 ng/mL of recombinant human CCL2 (Peprotech, Rocky Hill, NJ, USA). For CCL2 neutralization experiments, rabbit polyclonal antihuman CCL2 antibody (Abcam, ab9669) or rabbit IgG (Jackson ImmunoReserach, West Grove, PA, USA) was added to the tumour-conditioned media at 5 μg/mL immediately prior to addition of PBMCs. A total of 250 000 PBMCs in 100 L complete MEM were plated in the top well of the migration chamber insert. Subsequently, cells were allowed to migrate for 4 h under standard conditions of 37 ∘ C, 5% CO 2 , and humidified air. Following migration, the non-migrated cells were removed, and membranes were fixed with ice-cold methanol for 10 min on ice, stained with 3% crystal violet (Sigma-Aldrich), rinsed with dH 2 0, and air-dried overnight. The following day, membranes were cut from the cell culture inserts, and mounted 'migrated-side' up on superfrost plus glass slides using immersion oil. A total of (5) ×40 fields per membrane were counted to determine the Mean # of monocytes/×40 field for each membrane. Only cells displaying the appropriate nuclear and cytoplasmic characteristics consistent with monocytes were counted and included in the analysis. Neutrophils and lymphocytes were rarely observed on the migrated side of the membrane, but if present were excluded based on their segmented nuclear morphology, and nuclear:cytoplasmic ratio, respectively. Each migration assay was run in technical replicates at minimum, and each experiment was repeated at least once.
Serum and cell culture supernatant CCL2 analysis
A commercially available canine CCL2 ELISA kit (R&D Systems) was used to measure the concentration of CCL2 in tumour-conditioned cell culture media and in the serum of healthy control and HSA-bearing dogs. For in vitro assessment of CCL2 production by HSA tumour cells, 200 000 were plated in a 24-well plate in 1 mL of complete MEM media, and grown for approximately 24 h prior to harvesting the culture supernatants for ELISA assay. Because of the abundant amount of CCL2 produced by tumour cells, culture supernatants were diluted 1:20 (1:10 with MEM media, and 1:1 with the reagent diluent) prior to ELISA measurement, and a 7-point standard curve with a high standard of 4000 pg/mL was used to determine the concentration of CCL2 within the supernatant. Appropriate controls included cell culture media alone, diluted on a 1:1 ratio with reagent diluent, as well as other canine tumour cell lines (data not shown).
For analysis of serum CCL2 levels in HSA-bearing dogs, archived, frozen, serum samples from dogs with a histologically confirmed diagnosis of HSA (n = 24) were obtained from the tissue archive of the Flint Animal Cancer Center. For comparison, serum from 'healthy' control dogs (n = 6; median age = 10 years, range: 3-12 years) was obtained from personal pets of laboratory personnel or from the Clinical Pathology Laboratory at Colorado State University. These animals were deemed healthy based on their history, medical records and physical examination, and were not currently receiving any medications at the time of serum sampling.
Statistical analyses
For the comparison of mean values between three or more groups (% CD18+ area analysis, in vitro monocyte migration assays with CCL2 neutralization), a one-way ANOVA with Tukey's post-test was performed. For the comparison of means between two groups (in vitro monocyte migration assays, CCL2 ELISA assays of serum samples and tumour-conditioned media) a two-tailed, unpaired t-test was used. All statistical analyses were performed using Graph Pad Prism software (La Jolla, CA, USA).
Results
Immunohistochemical characterization of CD18 + cell infiltrates in pulmonary metastases of various canine tumour types
Positive immunostaining for CD18+ cells within pulmonary metastases was characterized by moderate to intense membranous to cytoplasmic labelling of individualized, round to sometimes slightly polygonal to elongate infiltrating immune cells (Fig. 1A-D) . These cells were easily distinguishable from tumour cells by their lack of cellular and nuclear pleomorphism. The CD18+ cells within metastases predominately consisted primarily of monocytes, along with a smaller population of CD18 + macrophages. The cellular features of the CD18+ cells included the following: (1) diameter larger than typical lymphocytes, containing a larger nucleus, increased cytoplasm and a lower nuclear:cytoplasmic ratio; and (2) typical mononuclear morphology, characterized by a round to U-shaped nucleus, lacking the nuclear segmentation typical of neutrophils (Fig. 2) .
Notably, despite the highly vascular nature of HSA, CD18 + cells within HSA metastases were predominately localized to the fibrous connective tissue stroma and connective tissue bundles forming the vascular spaces, and not within vascular spaces (see Fig. 2 ). In addition, HSA pulmonary metastases were often comprised of tumour cells arranged in sheets that resulted in an 'epithelioid' appearance, which allowed for easier image capture and analysis of CD18 + cell density, as opposed to the highly vascular morphological appearance associated with HSA of the spleen, liver, right atrium or elsewhere.
The micro-anatomical distribution and density of CD18 + cellular infiltrates within pulmonary metastases varied between tumour types. For HSA metastases, the CD18+ cells had the greatest density and degree of uniformity in cellular infiltrates (Fig. 1A) . For example, CD18+ cells were typically uniformly distributed, dense infiltrates throughout the tumour core, as well as forming dense rims three to five cell layers thick, which circumferentially surrounded the periphery of metastatic nodules (Fig.  S1 ). In contrast, CD18+ cells within soft tissue sarcoma and osteosarcoma metastases were more frequently arranged in small to medium-sized nodular clusters, randomly scattered throughout the tumour periphery and within the tumour core. Within melanoma and transitional cell carcinoma metastases, CD18+ cells were typically localized to within thin bands of reactive fibrous connective tissue stroma surrounding packets and nests of tumour cells, and were significantly less dense, individualized and frequently more polygonal to elongate in appearance (Fig. 1B-D) . Lastly, the density of CD18+ cells varied within each tumour type, with some tumours exhibiting markedly high degrees of CD18+ cellular infiltrates, while others cases were almost completely devoid of CD18+ cells.
CD18+ cellular infiltrates are greatest within HSA pulmonary metastases
For accurate quantitative assessment of CD18+ cells, we used the ImageJ colour deconvolution algorithm as described in Materials and methods. For each image, a mask of the positive area as determined by ImageJ was generated and directly compared with its 'parent' photomicrograph to ensure accuracy in automated assessment of CD18 immunoreactivity. As shown in Fig. S3 , the colour deconvolution algorithm was accurate in identifying CD18+ immunoreactivity, accurately selecting the Fast red chromogen signal localized to cellular membranes and cytoplasm, but at the same time excluding pigment, hyperchromatic nuclei, or other artefacts. Importantly, this algorithm was Figure 2 . Higher magnification image of CD18+ myeloid cell infiltrates within a hemangiosarcoma metastasis. CD18+ cells were typically characterized by a U-shaped to round, mononuclear morphology, consistent with either monocyte (thin arrows) or macrophage (thick arrows) morphology. Importantly, CD18+ cellular infiltrates were localized to the tumour stroma and thin fibrovascular septa forming the vascular spaces, and were not present within the lumens of neoplastic vessels. ×100 magnification. Fast red chromogen. Haematoxylin counterstain. also effective in discriminating the Fast red positive chromogen from the red hue of erythrocytes, thus preventing false positives resulting from the vascular nature of the HSA (black arrow, Fig. S3 ). The percentage of CD18+ area within tumour metastases was significantly greater within HSA, which had a mean of 11.75% (±2.913% positive area), when compared with transitional carcinoma metastases (6.229 ± 2.746%), and melanoma metastases (6.623 ± 3.245%) ( Fig. 3A; one-way ANOVA, Tukey's post-test, *P < 0.05). While the mean % CD18+ area within HSA metastases was numerically greater than for osteosarcoma (9.164 ± 4.168%) and soft tissue sarcoma metastases (8.924 ± 3.788%), but did not reach the level of statistical significance (P = 0.28 and 0.56, respectively). Importantly, the mean % CD18+ area within HSA metastases was significantly greater than the mean of the other tumour types combined (11.75 ± 0.69 versus 8.11 ± 0.76%, respectively) (P = 0.001).
CCL2 secreted by canine HSA cell line elicits strong monocyte migration.
A canine HSA cell line (DEN-HSA) was used to investigate the immunological mechanisms responsible for monocyte infiltrates observed in Figure 3 . Quantification of CD18+ cell density within pulmonary metastases using ImageJ colour deconvolution. (A) The density of C18+ cells, expressed as CD18+ area as percentage of tumour area, was greatest within hemangiosarcoma metastases and was significantly greater than that observed in transitional cell carcinoma and melanoma metastases. (B) Furthermore, the percentage of CD18+ cells were even more significantly greater in hemangiosarcoma metastases, when compared with all other evaluated tumour types combined. HSA, hemangiosarcoma; OSA, osteosarcoma; STS, soft tissue sarcoma; TCC, transitional cell carcinoma. Data representative of mean ± SD. *P = 0.03 (HSA versus melanoma) and *P = 0.04 (HSA versus TCC); one-way ANOVA, Tukey's post-test; **P = 0.001; unpaired, two-tailed t-test.
HSA metastases. A monocyte migration assay was used to evaluate the effects of DEN-HSA conditioned medium on monocyte recruitment, using canine PBMC from healthy control dogs and trans-well plates (Fig. 4A-C) . Following exposure of PBMC to HSA-conditioned medium, the Representative photomicrographs of crystal violet stained membranes of the cell culture inserts used for quantification of in vitro monocyte migration. Complete MEM media stimulated little to no monocyte migration (A); however, conditioned media from canine DEN-HSA cells stimulated strong monocyte migration (C), which was significantly greater than the negative control, and at minimum equivalent to the positive control of 100 ng/mL recombinant human rCCL2 (B). Only migrated cells displaying a mononuclear morphology consistent with monocytes were counted and included in the analysis. (D) Quantitative assessment of monocyte migration to media alone (negative control), 100 ng/mL recombinant human CCL2 (positive control), or HSA-conditioned media. Each data point represents the mean (±SD) number of monocytes per ×40 field for duplicate membranes as determined by counting (5) independent ×40 fields per membrane. *P < 0.05, repeated measures one-way ANOVA, Tukey's post-test. All images are ×40 magnification and crystal violet stained. [Colour figure can be viewed at wileyonlinelibrary.com] mean number of migrated monocytes per HPF (24.7 ± 10.02) was significantly increased compared with control medium (1.6 ± 2.054) (P < 0.05 (Fig. 4) . In addition, CCL2 secreted by DEN-HSA cells was quantified using a canine CCL2 ELISA, as described previously. 42 DEN-HSA conditioned media contained very high concentrations of CCL2 (Fig. 5C) , with a mean concentration of 22 830 pg/mL (Fig. 4) . Furthermore, a second canine HSA cell line (SB-HSA) was evaluated for CCL2 production by ELISA assay, and was found to also produce significant amounts of the chemokine (Fig. S4) . Next, immunofluorescence staining was used to localize tumour cell production of CCL2. Cross-reactivity of a polyclonal CCL2 antibody for canine CCL2 was confirmed via western blotting against recombinant canine CCL2 (Fig. S2) . The antibody detected a band of approximately 15 kDa, consistent with the predicted molecular weight of canine CCL2 (8-12 kDa). DEN-HSA cells were pre-incubated with the protein transport inhibitor Brefeldin A (10 μg/mL) for 4 h prior to staining. DEN-HSA cells exhibited strong CCL2 positive immunoreactivity, characterized by punctate to granular staining which discretely localized to the perinuclear Golgi zone of the cytoplasm (Fig. 5B) .
To elucidate the factor produced by DEN-HSA cells that stimulated monocyte migration, the DEN-HSA-conditioned medium was incubated with a neutralizing CCL2 antibody, and the effects on monocyte migration assessed. Addition of Figure 5 . Canine hemangiosarcoma cells produce abundant amounts of CCL2 in vitro and elicit canine monocyte migration in a CCL2-CCR2 dependent manner. Immunolabelling of DEN-HSA cells for CCL2 required pretreatment with a protein transport inhibitor (Brefeldin A). Un-treated cells (A) displayed no immunoreactivity for CCL2, whereas cells pretreated with Brefeldin A (B), demonstrated, strong, punctate, perinuclear immunoreactivity for CCL2, which is more clearly demonstrated in the enlarged single cell image inset. ×40 magnification. CCL2 = FITC (green). Nuclei = DAPI (blue) (C) Significant amounts of CCL2 was also detected via ELISA in conditioned media from DEN-HSA cells. Tumour cells were seeded in 24-well plates and allowed to grow for 24 h prior to harvesting the supernatant for CCL2 measurement via ELISA assay. (D) Neutralization of CCL2 in HSA-conditioned media using an antihuman CCL2 antibody (5 μg/mL) resulted in a significant (∼60-80%) reduction in in vitro monocyte migration when compare with the positive control of HSA-conditioned media only. Data representative of mean ± SD. **P = 0.006 unpaired one-tailed t-test; ***P = 0.0002; ****P < 0.0001. One-way ANOVA, Tukey's post-test. the CCL2 neutralizing antibody to the tumourconditioned media significantly reduced the number of migrated monocytes to approximately 60-80% of that observed for HSA-conditioned media alone (***P = 0.0002) (Fig. 5D ). These findings indicated that DEN-HSA in vitro elicited monocyte migration was mediated primarily by CCL2 secretion.
Immunohistochemical localization of CCL2 in HSA pulmonary metastases
Expression of CCL2 in tumour biopsy specimens was almost entirely restricted to tumour cells, with between 50 and 100% of tumour cells within metastatic nodules demonstrating moderate to strong labelling intensity for CCL2 ( Figure 6A and Fig. S5A) . Within tumour cells, the localization of CCL2 immunoreactivity varied from diffuse and intracytoplasmic, to focal, intense and perinuclear (Fig. 6B) . In addition, most osteosarcoma pulmonary metastases also displayed positive CCL2 labelling, although the pattern of immunoreactivity was typically characterized by weak cytoplasmic labelling for CCL2. Metastatic transitional cell carcinoma tumours demonstrated diffuse, intense, cytoplasmic labelling for CCL2, which was present in 75-100% of tumour cells. Lastly, only one of three metastatic melanoma biopsies demonstrated positive immunolabelling of tumour cells for CCL2. Thus, while there was a wide range of CCL2 expression by different types of tumour cells, HSA metastases were the most consistently strongly CCL2 positive.
Serum CCL2 levels elevated in the blood of dogs with splenic HSA CCL2 concentrations in the pretreatment serum of 24 dogs with a histopathologically confirmed diagnosis of HSA, were measured using an ELISA assay as described above. For comparison, CCL2 concentrations were also measured in the serum of six age-matched, healthy control dogs. The median age of HSA-bearing dogs was 9.8 years (range of 7-15 years), and consisted of 12 males and 12 females. The median age of the healthy control dogs was 10 years (range of 3-12 years), and consisted of three males and three females. The mean concentration of CCL2 in the serum of HSA-bearing dogs (267.4 ± 56.64 pg/mL) was significantly elevated (Fig. 7) compared with healthy control dogs (123.9 ± 50.68 pg/mL). Values for serum CCL2 concentration were significantly elevated compared with control dogs, whether evaluating dogs with HSA of any primary location, or only dogs with primary splenic HSA (data not shown).
Discussion
Experimental and clinical evidence strongly suggests that monocytes promote tumour metastasis in humans and rodent tumour models, but the role of monocytes in canine tumour metastasis has received relatively little attention. Therefore, a primary goal of the current study was to characterize the degree of monocyte infiltration within pulmonary metastases of common and highly metastatic canine tumours of dogs. One of the most important findings that emerged from these studies was that HSA pulmonary metastases appear to have a unique propensity in their ability to recruit monocytes, as these tumours demonstrated a significantly greater degree of CD18 + monocyte infiltration when compared with all other evaluated canine tumour metastases (Figs 1-3) . These findings were bolstered by also demonstrating strong CCL2 immunostaining of tumour metastases (Fig. 6 ). In addition, in vitro assays were used to show that HSA cells secreted high concentrations of CCL2, which strongly stimulated monocyte migration (Figs 6 and 7) . Thus, it is apparent from these results that the CCL2-CCR2 axis plays an important role in monocyte recruitment in HSA in dogs.
Given that HSA is an endothelial-derived tumour, and monocytes are known to be a rich source of the endothelial growth factor VEGF, 24 our findings suggest one important role for monocytes in HSA, namely stimulation of tumour angiogenesis. Interestingly, haematopoietic stem/progenitor cells of a CD11b + myelo-monocytic phenotype are also one of cell types that preferentially accumulate at metastatic sites even before the arrival of tumour cells, a phenomenon known as the premetastatic niche. 43 -45 This phenomenon has been demonstrated experimentally in syngeneic mouse models of lung carcinoma and melanoma, as well as a human xenograft breast cancer model. 43 -45 In addition, increased numbers of these cells have been detected in human cancer patients and correlate with increased risk for metastatic progression. 43 Once present at metastatic sites, monocytes function to establish a permissive niche for incoming tumour cells through mechanisms involving immune suppression, up-regulation of tumour cell chemoattractants and promotion of tumour cell survival, both directly via secretion of molecules such as S100A8 and A9, and matrix metalloproteinase-mediated release of VEGF and c-KIT. 43 -45 Furthermore, the functional impact of monocytes on metastatic progression has been confirmed experimentally, as antibody-mediated depletion of these cells completely prevented metastasis in mice bearing well-established tumours. 45 The role of inflammatory monocytes and macrophages in the regulation of tumour responses to chemotherapeutic drugs is also beginning to be defined. Importantly, the functional role of monocytes and macrophages in mediating chemoresistance has been demonstrated via preclinical studies in which concurrent macrophage depletion with chemotherapy significantly improved overall survival in mammary tumour bearing mice. 46, 47 In addition, clinical evidence supporting a role for macrophages in chemoresistance comes from human breast cancer patients, in which patients having a high tumour gene expression ratio of macrophages to T cells had a significantly lower rate of response to neoadjuvant chemotherapy, and significantly reduced overall survival. 46 Thus, the results of our study and the significant presence of monocytes in HSA metastases may be related to the tumours apparent lack of chemotherapy responsiveness. For example, our findings suggest that in canine HSA, the typical poor response to adjuvant chemotherapy may in fact be mediated by the strong monocyte infiltrate present in tumour metastases.
In conclusion, we found that canine HSA, when compared with other common and highly metastatic canine tumours types, was unique in its ability to recruit large numbers of monocytes to sites of tumour metastasis. Moreover, our results suggest that the CCL2-CCR2 chemotactic axis may be the primary driver of this monocyte response. These observations provide important insights into the biology and immunopathogenesis of HSA, and are consistent with the hypothesis that overexpression of CCL2 and recruitment of large numbers of monocytes may explain in part the aggressive metastatic nature of canine HSA. Thus, treatment strategies designed to exploit this monocyte driven response, such as treatment with monocyte depleting agents (e.g. liposomal clodronate 48 ) or migration inhibitors (e.g. CCL2 depleting antibodies or CCR2 antagonists) could be explored to improve the effectiveness of conventional adjuvant chemotherapy for prevention of HSA metastases.
Supporting Information
Additional Supporting Information may be found in the online version of this article: Figure S1 . Overview of the distribution of CD18+ cells within hemangiosarcoma metastases. Low-magnification image demonstrating CD18+ cells localized both circumferentially around the periphery of metastatic nodules (black arrows), as well as diffusely infiltrating through the tumour stroma and core of metastatic nodules. ×10 magnification. Fast red chromogen. Haematoxylin counterstain. Figure S2 . Cross-species validation of the antihuman CCL2 antibody and isotype control staining of pulmonary metastases for CCL2. (A) Cross-reactivity of the antihuman CCL2 antibody was confirmed via western blot against canine recombinant CCL2 (R&D systems, Minneapolis, MN, USA), which detected a band of ≈15 kDa (predicted M.W. of 8-12 kDa). (B) Concentration-matched, rabbit IgG negative control for CCL2 staining of FFPE metastatic tumour tissues demonstrating a complete lack of immunoreactivity within tumour tissues. ×20 magnification. DAB chromogen, haematoxylin counterstain. Figure S3 . Validation of the ImageJ colour deconvolution algorithm for quantitative assessment of CD18+ cell density. (A) Original ×40 image of CD18+ immunolabelling, and (B) corresponding quality control, thresholded image mask of CD18 positive area as determined in ImageJ using the colour deconvolution algorithm. Colour deconvolution with the Fast red and Fast blue vectors followed by setting a lower threshold limit at the mean grey value of negative control images generated effective masks for accurate quantitative evaluation of CD18 + cellular infiltrates. Figure S4 . A significant amounts of CCL2 was also detected via ELISA in conditioned media from a second canine hemangiosarcoma cell line (SB-HSA). As described for the DEN-HSA cells, tumour cells were seeded in 24-well plates and allowed to grow for 24 h prior to harvesting the supernatant for CCL2 measurement via ELISA assay. Data representative of mean ± SD. **P = 0.001 unpaired two-tailed t-test. 
